Rimegepant: New Hope for Chronic Migraine Prevention

Research Summary

A recent study published in Cephalalgia explored the efficacy and tolerability of rimegepant for preventing episodic migraines in adults who had previously not responded adequately to traditional oral preventive medications. This Phase 4 trial involved 652 participants with 4-14 monthly migraine days, randomized to receive either rimegepant or a placebo every other day. Results showed that rimegepant significantly reduced monthly migraine days by 2.1 compared to 0.5 days with placebo. All key secondary endpoints favored rimegepant, including improvements in migraine-related quality of life. Rimegepant was well tolerated, with a safety profile similar to placebo, making it a promising option for migraine prevention.

Study Details

📄 Title: A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.

👥 Research Team: Pozo-Rosich P et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.